第一单位：
Vall d'Hebron University Hospital, Department of Gynecologic Oncology, Barcelona, Spain.
作者：
Ana,Luzarraga Aznar [1]
;
Roger,Canton [2]
;
Guillem,Loren [2]
;
Javier,Carvajal [2]
;
Irene,de la Calle [3]
;
Carina,Masferrer-Ferragutcasas [3]
;
Francesc,Serra [3]
;
Vicente,Bebia [4]
;
Giulio,Bonaldo [1]
;
Martina Aida,Angeles [4]
;
Silvia,Cabrera [5]
;
Núria,Palomar [2]
;
Cristina,Vilarmau [2]
;
Maria,Martí [2]
;
Marina,Rigau [2]
;
Eva,Colas [6]
;
Antonio,Gil-Moreno [7]
作者单位：
Vall d'Hebron University Hospital, Department of Gynecologic Oncology, Barcelona, Spain.
[1]
MiMARK Diagnostics SL, Parc Científic de Barcelona, Barcelona, Spain.
[2]
Universitat Autònoma de Barcelona, Vall d'Hebron Institute of Research, Biomedical Research Group in Gynecology, CIBERONC, Barcelona, Spain.
[3]
Vall d'Hebron University Hospital, Department of Gynecologic Oncology, Barcelona, Spain; Universitat Autònoma de Barcelona, Vall d'Hebron Institute of Research, Biomedical Research Group in Gynecology, CIBERONC, Barcelona, Spain.
[4]
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
[5]
MiMARK Diagnostics SL, Parc Científic de Barcelona, Barcelona, Spain; Universitat Autònoma de Barcelona, Vall d'Hebron Institute of Research, Biomedical Research Group in Gynecology, CIBERONC, Barcelona, Spain.
[6]
Vall d'Hebron University Hospital, Department of Gynecologic Oncology, Barcelona, Spain; MiMARK Diagnostics SL, Parc Científic de Barcelona, Barcelona, Spain; Universitat Autònoma de Barcelona, Vall d'Hebron Institute of Research, Biomedical Research Group in Gynecology, CIBERONC, Barcelona, Spain. Electronic address: antonio.gil@vallhebron.cat.
[7]
DOI
10.1016/j.ijgc.2024.100056
PMID
40011116
发布时间
2025-04-12
换一批
